Enzyme, AEB3103, Kills Prostate Cancer Cells by Unleashing Oxidative Stress in Mice Study

Enzyme, AEB3103, Kills Prostate Cancer Cells by Unleashing Oxidative Stress in Mice Study
Aeglea BioTherapeutics' investigational enzyme, AEB3103, seems a promising treatment approach for a number of tumors, according to preclinical study results. The therapy suppressed tumor growth in prostate and breast cancer mouse models, and improved survival in a model of chronic lymphocytic leukemia (CLL). These findings, published in the journal Nature Medicine, were detailed in the study, “Systemic Depletion Of Serum L-Cyst(E)Ine With An Engineered Human Enzyme Induces Production Of Reactive Oxygen Species And Suppresses Tumor Growth In Mice.” High activity within cells leads to the production of unstable molecules called reactive oxygen species (ROS) within the mitochondria (the cell’s powerhouse). Usually, cells use antioxidants, such as the protein glutathione, to ‘clean’ themselves of ROS. But when ROS are produced at too fast a pace and accumulate, antioxidant defenses are not enough to protect cells from their damaging effects. Cancer cells experience greater oxidative stress than healthy cells due to the genetic alterations they harbor and their abnormal growth. As such, maintaining antioxidant defenses against ROS is crucial to cancer's survival and growth. In the studies, AEB3103 given to mice with prostate or breast cancer, or used in a model of human CLL, deprived cancer cells of an important activator of the antioxidant glutathione, called L-cysteine. Its lack promoted ROS accumulation, increasing oxidative damage to, and cell death in, the cancer cells. AEB3103, an engineered human enzyme, works to degrade L-cysteine in the blood into non-toxic metabolites. “These preclini
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *